Table 2 Patient characteristics and transplant-related parameters in the haplo-HSCT groups.
Variable | Haplo-PTCy group (n = 22) | Haplo-control group (n = 15) | P values |
|---|---|---|---|
Median age in years (range) | 14 (3–31) | 8 (2–32) | 0.277 |
Sex(male/female) | 13/9 | 9/6 | 1.000 |
Classification | |||
SAA-I | 13 | 9 | |
SAA-II | 9 | 6 | 1.000 |
Prior treatment | |||
Steroids/cyclosporine | 21 | 14 | |
ATG/ALG | 1 | 1 | 1.000 |
Time from diagnosis to HSCT | |||
median months (range) | 13.5 (1–102) | 7 (1–36) | 0.028* |
Median donor age in Years (range) | 30 (4–53) | 30 (17–53) | 0.377 |
Donor/recipient sex | |||
Female/female | 3 | 1 | |
Female/male | 3 | 1 | |
Male/female | 6 | 5 | |
Male/male | 10 | 8 | 0.795 |
HLA mismatch class | |||
Class I mismatch (HLA A, B, C) | 16 | 11 | |
Class II mismatch (HLA DRB1, DQB1) | 6 | 4 | 1.000 |
ABO incompatibility | |||
None | 12 | 10 | |
Minor | 4 | 2 | |
Major | 6 | 3 | 0.762 |
Graft source | |||
PBSCs | 20 | 0 | |
PBSCs and BM | 2 | 15 | < 0.0001**** |
UC-MSCs | 22 | 0 | < 0.0001**** |
Donor-specific antibody | 2 | 0 | 0.505 |
Cell dose (median) | |||
MNCs × 108/kg | 18.73 (8.41–32.35) | 23.43 (2.02–31.72) | 0.308 |
CD34 + cells × 106/kg | 7.60 (4.21–19.45) | 8.95 (1.76–22.53) | 0.522 |
